Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 6/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | MITF | O75030 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.44 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7213531 | 0.81 | ALDH1A1 (0.62) | CHRM2CHRM3MEN1KMT2AALDH1A1 | |
| SCHEMBL4486860 | 0.81 | MEN1 (0.68) | MEN1KMT2AKDM4ELMNAALOX15 | |
| SCHEMBL9001635 | 0.79 | CHRM2 (0.62) | CHRM2CHRM3MEN1KMT2AALDH1A1 | |
| SCHEMBL8387718 | 0.78 | MEN1 (0.49) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL4488042 | 0.78 | ALDH1A1 (0.59) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| SCHEMBL9845445 | 0.75 | MEN1 (0.51) | CHRM3MEN1KMT2AALDH1A1KDM4E | |
| SCHEMBL13903891 | 0.74 | ALDH1A1 (0.64) | CHRM2CHRM3MEN1KMT2AALDH1A1 | |
| SCHEMBL7375602 | 0.74 | TRPM8 (0.57) | CHRM2CHRM3KDM4ENPC1RAB9A | |
| SCHEMBL28238966 | 0.73 | MEN1 (0.40) | CHRM2CHRM3MEN1KMT2AALDH1A1 | |
| SCHEMBL28017518 | 0.73 | CHRM2 (0.50) | CHRM2CHRM3MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | claimed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | claimed |
| CN-101336227-A | Nuclear receptor binding agents | GTX INC (US) | 2008-12-31 | — | — | CN | claimed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | claimed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | claimed |
| US-9409856-B2 | Estrogen receptor ligands and methods of use thereof | GTX, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| CN-102702013-B | Nuclear receptor binding agents | GTX INC. (US) | 2016-02-10 | — | — | CN | disclosed |
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | GTX, INC. | 2016-02-04 | — | — | US | disclosed |
| CN-102351732-B | Nuclear receptor binding agents | GTX INC. (US) | 2014-10-29 | — | — | CN | disclosed |
| US-8637706-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. | 2012-06-21 | — | — | US | disclosed |
| EP-2455362-A1 | Nuclear receptor binding agents | GTX, Inc. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-8158828-B2 | Nuclear receptor binding agents | GTX, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090062341-A1 | Nuclear receptor binding agents | GTX, INC | 2009-03-05 | — | — | US | disclosed |
| CN-101336227-A | Nuclear receptor binding agents | GTX INC (US) | 2008-12-31 | — | — | CN | disclosed |
| WO-2008130571-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1954670-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| US-20070265296-A1 | Nuclear receptor binding agents | GTX, INC. | 2007-11-15 | — | — | US | disclosed |
| WO-2007062230-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160031797-A1 | ESTROGEN RECEPTOR LIGANDS AND METHODS OF USE THEREOF | ESRRB, ESRRA, ESR2 | CHRM2 2807/4885CHRM3 1526/4885MEN1 3937/4885 |
| US-20070265296-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | CHRM2 980/4885CHRM3 481/4885MEN1 1408/4885 |
| US-20090062341-A1 | Nuclear receptor binding agents | GPER1, ESRRG, ESR2 | CHRM2 980/4885CHRM3 481/4885MEN1 1408/4885 |
| US-20120157539-A1 | NUCLEAR RECEPTOR BINDING AGENTS | GPER1, ESRRG, ESR2 | CHRM2 980/4885CHRM3 481/4885MEN1 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.